Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics


Viking Therapeutics, Inc. (VKTX): $11.65

-0.18 (-1.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VKTX Stock Price Chart Interactive Chart >

Price chart for VKTX

VKTX Price/Volume Stats

Current price $11.65 52-week high $11.98
Prev. close $11.83 52-week low $2.02
Day low $10.95 Volume 2,933,632
Day high $11.92 Avg. volume 2,005,018
50-day MA $10.08 Dividend yield N/A
200-day MA $5.34 Market Cap 913.58M

Viking Therapeutics, Inc. (VKTX) Company Bio


Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.


VKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

VKTX Latest Social Stream


Loading social stream, please wait...

View Full VKTX Social Stream

Latest VKTX News From Around the Web

Below are the latest news stories about VIKING THERAPEUTICS INC that investors may wish to consider to help them evaluate VKTX as an investment opportunity.

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Viking Therapeutics...

Yahoo | March 15, 2023

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences.

Yahoo | March 7, 2023

2 Surging Healthcare Stocks That Are Still Worth Buying

Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX) bucked this downward trend in a big way. Here's why these two surging healthcare stocks are still worth buying right now. Madrigal's shares have been charging higher of late in response to a positive late-stage readout for its lead product candidate, resmetirom, in nonalcoholic steatohepatitis (NASH).

Yahoo | February 23, 2023

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Earnings Call Transcript

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Earnings Call Transcript February 8, 2023 Operator: Welcome to the Viking Therapeutics Fourth Quarter and Full-year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question and answer session. As a reminder, this conference call […]

Yahoo | February 11, 2023

Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its clinical pipeline and other corporate developments.

Yahoo | February 8, 2023

Read More 'VKTX' Stories Here

VKTX Price Returns

1-mo 3.19%
3-mo 62.03%
6-mo 300.34%
1-year 245.70%
3-year 169.68%
5-year 118.57%
YTD 23.94%
2022 104.35%
2021 -18.29%
2020 -29.80%
2019 4.84%
2018 88.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7492 seconds.